Navidea Biopharmaceuticals Inc (OTCPK:NAVB)
$ 0.0001 0 (0%) Market Cap: 10,000.00 Enterprise Value: -2.60 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 0/100

Q4 2018 Navidea Biopharmaceuticals Inc Earnings Call Transcript

Mar 07, 2019 / 10:00PM GMT
Release Date Price: $3.4 (+4.94%)
Operator

Greetings, and welcome to Navidea Biopharmaceuticals Fourth Quarter 2018 Earnings Conference Call and Business Update. (Operator Instructions) As a reminder, this conference is being recorded.

I would now like to turn the conference over to your host, Jed Latkin.

Jed A. Latkin
Navidea Biopharmaceuticals, Inc - CEO, COO, CFO, Secretary, Treasurer & Director

Thank you, Dana. Good afternoon, and welcome everyone to Navidea's Fourth Quarter 2018 Earnings Call. I am Jed Latkin, Chief Executive Officer of Navidea Biopharmaceuticals. This call will cover Navidea's financial and operating results for the fourth quarter of 2018, which ended on December 31, 2018, along with a discussion of goals and milestones for 2019. Following our prepared remarks, we will open up the conference call to a question-and-answer session.

With me on our call today is our Director of Finance and Administration, Erika Gibson; and our Chief Medical Officer, Dr. Mike Rosol.

But before we begin our formal remarks, I would like to remind everyone that some of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot